Commonwealth of Pennsylvania Public School Empls Retrmt SYS Acquires 2,220 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDMGet Rating) by 10.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,284 shares of the medical device company’s stock after purchasing an additional 2,220 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Tandem Diabetes Care were worth $2,708,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of TNDM. Exane Derivatives bought a new stake in Tandem Diabetes Care in the 1st quarter valued at about $33,000. Byrne Asset Management LLC bought a new stake in shares of Tandem Diabetes Care during the 4th quarter worth approximately $34,000. CI Investments Inc. lifted its holdings in shares of Tandem Diabetes Care by 10,566.7% during the 1st quarter. CI Investments Inc. now owns 320 shares of the medical device company’s stock worth $37,000 after acquiring an additional 317 shares during the period. Sandy Cove Advisors LLC bought a new stake in shares of Tandem Diabetes Care during the 1st quarter worth approximately $46,000. Finally, KRS Capital Management LLC bought a new stake in shares of Tandem Diabetes Care during the 4th quarter worth approximately $60,000. Institutional investors own 95.28% of the company’s stock.

Tandem Diabetes Care Trading Up 4.3 %

Shares of NASDAQ TNDM opened at $45.65 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 5.36 and a current ratio of 6.00. Tandem Diabetes Care, Inc. has a 52-week low of $42.90 and a 52-week high of $155.86. The firm has a 50 day moving average price of $55.71 and a two-hundred day moving average price of $78.95. The stock has a market cap of $2.93 billion, a P/E ratio of -207.50 and a beta of 0.95.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on TNDM shares. Lake Street Capital cut their price target on shares of Tandem Diabetes Care from $200.00 to $150.00 in a report on Thursday, August 4th. Wells Fargo & Company downgraded shares of Tandem Diabetes Care from an “overweight” rating to an “underweight” rating and dropped their price objective for the company from $82.00 to $49.00 in a research note on Tuesday, August 9th. Raymond James dropped their price objective on shares of Tandem Diabetes Care from $125.00 to $90.00 and set an “outperform” rating for the company in a research note on Thursday, August 4th. Cowen dropped their price objective on shares of Tandem Diabetes Care from $141.00 to $107.00 in a research note on Thursday, August 4th. Finally, OTR Global downgraded shares of Tandem Diabetes Care to a “positive” rating in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $103.36.

Tandem Diabetes Care Profile

(Get Rating)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Articles

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.